Both coronavirus disease 2019 (COVID-19) and severe acute respiratory syndrome (SARS) are characterised by an overexuberant inflammatory response and, for SARS, viral load is not correlated with the worsening of symptoms.^,  In our previous Correspondence to The Lancet, we described how BenevolentAI's proprietary artificial intelligence (AI)-derived knowledge graph, queried by a suite of algorithms, enabled identification of a target and a potential therapeutic against SARS coronavirus 2 (SARS-CoV-2; the causative organism in COVID-19). We identified a group of approved drugs that could inhibit clathrin-mediated endocytosis and thereby inhibit viral infection of cells (). The drug targets are members of the numb-associated kinase (NAK) family—including AAK1 and GAK—the inhibition of which has been shown to reduce viral infection in vitro.^,  Baricitinib was identified as a NAK inhibitor, with a particularly high affinity for AAK1, a pivotal regulator of clathrin-mediated endocytosis. We suggested that this drug could be of use in countering SARS-CoV-2 infections, subject to appropriate clinical testing.

中文翻译：

---

COVID-19：结合抗病毒和抗炎治疗。

2019 年冠状病毒病 (COVID-19) 和严重急性呼吸系统综合症 (SARS) 的特点是炎症反应过度旺盛，对于 SARS，病毒载量与症状恶化无关。^， 在我们之前对《柳叶刀》的通讯中，我们描述了 BenevolentAI 的专有人工智能 (AI) 衍生知识图谱，通过一套算法查询，如何识别目标和针对 SARS 冠状病毒 2（SARS-CoV-2；COVID-19 中的致病微生物）的潜在治疗方法）。我们确定了一组已获批准的药物，它们可以抑制网格蛋白介导的内吞作用，从而抑制细胞的病毒感染。药物靶点是麻木相关激酶 (NAK) 家族的成员——包括 AAK1 和 GAK——已证明其抑制可减少体外病毒感染。^, Baricitinib 被鉴定为 NAK 抑制剂，对 AAK1 具有特别高的亲和力，AAK1 是网格蛋白介导的内吞作用的关键调节因子。我们建议这种药物可用于对抗 SARS-CoV-2 感染，但需要进行适当的临床测试。